Vimarsana
Biggest News Aggregation in the World

Page 4 - Nasdaq Elev News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Elev. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Elev Today - Breaking & Trending Today

Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Update - Vimarsana News

Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Update

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 1,030,000 shares, a growth of 688.7% from the April 15th total of 130,600 shares. Based on an average daily volume of 766,300 shares, the short-interest ratio is presently 1.3 days. […]

Source: wkrb13.com
Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Update - Vimarsana News

Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Update

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 123,200 shares, an increase of 135.6% from the March 15th total of 52,300 shares. Approximately 0.8% of the shares of the company are sold short. Based on […]

Source: wkrb13.com
Elevation Oncology (ELEV) and Its Rivals Head to Head Survey - Vimarsana News

Elevation Oncology (ELEV) and Its Rivals Head to Head Survey

Elevation Oncology (NASDAQ:ELEV – Get Rating) is one of 255 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Elevation Oncology to similar companies based on the strength of its profitability, valuation, risk, earnings, dividends, institutional ownership and analyst recommendations. Insider & […]

Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) Target Price at $17.82 - Vimarsana News

Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) Target Price at $17.82

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) has earned a consensus rating of “Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among […]